BioDlink International (HKG:1875) said there were no undisclosed matters that would warrant an unusual movement in its stock's price, according to a Hong Kong bourse filing Tuesday.
Shares of the drug maker gained 1% in late morning trade Wednesday.
Related Articles
Asia
International Entertainment Issues HK$800 Million Convertible Bond to DigiPlus in Second Tranche
International Entertainment (HKG:1009) completed the second and final tranche of its convertible bond issuance, issuing HK$800 million in notes to Philippine online gambling platforms operator DigiPlus Interactive (PSE:PLUS), according to a Tuesday Hong Kong bourse filing.The issuance was part of a subscription agreement signed in November 2025 for convertible notes with an aggregate principal amount of up to HK$1.6 billion.The first tranche of notes with a principal amount of HK$800 million was issued in March.Net proceeds will be used partly to repay promissory notes and bank borrowings, fund the development of an integrated resort project in Manila, and for general working capital, the firm previously said.
$HKG:1009$PSE:PLUS
Asia
Market Chatter: China Sees Rebound in LNG Imports in May
China's liquefied natural gas imports rose to 4.9 million tons in May, marking a marginal year-on-year increase. The rebound offers a stark contrast to April's imports, which hit an eight-year low, with the country raising purchases to satisfy summer demand, Bloomberg News reported Tuesday.The Iran war has choked Gulf shipments, which typically supply one-third of China's needs. Qatar's drop was offset by increases from Canada, Malaysia, Oman and Russia, according to the report.State-owned CNOOC (SHA:600938, HKG:0883) and Zhejiang Energy have purchased cargoes for June and July delivery amid falling inventories and expected hot summer weather, Bloomberg wrote.(Market Chatter news is derived from conversations with market professionals globally. This information is believed to be from reliable sources but may include rumor and speculation. Accuracy is not guaranteed.)
$^SSEC$^SZSE$HKG:0883$SHA:600938
Asia
Pell Bio Med Unit Gets China's Regulatory Nod for Rheumatoid Arthritis Drug Trail
Pell Bio Med Technology (TPE:6949) unit Peptide (Shanghai) Pharmaceutical Technology secured approval from China's National Medical Products Administration (NMPA) to begin the Phase I clinical trial for its oral drug candidate PP011, according to a Tuesday Taiwan Exchange filing.The trial will be conducted in healthy subjects and targets rheumatoid arthritis (RA), marking the first human study for the novel therapy.The company said the development program is planned through Phase two and Phase three trials before potential new drug application submission.Phase one completion is expected in the first quarter of 2027, it said.
$TPE:6949